Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 10,085	$ 15,045
Prepaid expenses and other current assets	1,084	1,381
Total Current Assets	11,169	16,426
Property and equipment, net	309	367
Right of use asset	386	419
Deposits and other assets	23	23
Total Assets	11,887	17,235
Current Liabilities:
Accounts payable	1,247	2,315
Accrued expenses	1,062	1,776
Accrued employee benefits	309	935
Lease liability	258	249
Total Current Liabilities	2,876	5,275
Lease liability - Long term	405	473
Total Liabilities	3,281	5,748
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding	12,606	12,544
Stockholders' Deficit:
Common stock, $0.001 par value; 200,000,000 shares authorized, 17,741,803, issued and 17,739,475 outstanding and 16,808,758, issued and 16,806,430 outstanding	18	17
Additional paid-in capital	233,735	232,580
Accumulated deficit	(238,967)	(235,537)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit	(1,122)	1,821
Non-controlling interest	(2,878)	(2,878)
Total Stockholders' Deficit	(4,000)	(1,057)
Total Liabilities and Stockholders' Deficit	11,887	17,235
Series B Preferred Stock [Member]
Stockholders' Deficit:
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 6,565 issued and outstanding and 7,638 issued and outstanding	4,092	4,761
Total Stockholders' Deficit	$ 4,092	$ 4,761